2009
DOI: 10.1002/hep.23376
|View full text |Cite
|
Sign up to set email alerts
|

Results of the IDEAL trial: “Mirror, mirror on the wall … Which's the fairest peg-interferon of them all?”

Abstract: Results of the IDEAL Trial: "Mirror, Mirror on the Wall . . . Which's the Fairest PegInterferon of Them All?" McHutchison JG, Lawitz EJ, Shiffman ML, Muir AJ, Galler GW, McCone J, et al.; AbstractTreatment guidelines recommend the use of peginterferon alfa-2b or peginterferon alfa-2a in combination with ribavirin for chronic hepatitis C virus (HCV) infection. However, these regimens have not been adequately compared. Methods: At 118 sites, patients who had HCV genotype 1 infection and who had not previously… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
2
0

Year Published

2010
2010
2014
2014

Publication Types

Select...
5

Relationship

0
5

Authors

Journals

citations
Cited by 5 publications
(2 citation statements)
references
References 19 publications
0
2
0
Order By: Relevance
“…The majority of patients received PEG interferon alpha 2a [29], three patients who were treated early in 2000 still received conventional non-pegylated interferon. New direct-acting antiviral agents for hepatitis C genotype 1 infection, such as boceprevir, telaprevir or simeprevir as well as sofosbuvir [17,18,30,31], were not approved yet during the analysed timeperiod.…”
Section: Discussionmentioning
confidence: 99%
“…The majority of patients received PEG interferon alpha 2a [29], three patients who were treated early in 2000 still received conventional non-pegylated interferon. New direct-acting antiviral agents for hepatitis C genotype 1 infection, such as boceprevir, telaprevir or simeprevir as well as sofosbuvir [17,18,30,31], were not approved yet during the analysed timeperiod.…”
Section: Discussionmentioning
confidence: 99%
“…The study was originally designed to fulfil a postapproval commitment to the FDA to determine the appropriate dose of PegIFN α2b in patients with HCV genotype 1, i.e., low‐dose (LD) therapy at 1.0 μg/kg/week vs the standard dose (SD) of 1.5 μg/kg/week, both plus Rbv; however, the most awaited result was the direct comparison with the 180 μg/week PegIFN α2a plus Rbv treatment. The final results created some turmoil in the Hepatology community [25–28]. The three regimens yielded similar SVR rates (PegIFN α2b LD and SD: 38% and 39.8%; PegIFN α2a: 40.9%); however, the PegIFN α2a arm had a higher end of treatment response rate (PegIFN α2b LD and SD: 49.2% and 53.2%; PegIFN α2a: 64.4%) that in turn was counterbalanced by a higher posttreatment relapse rate (PegIFN α2b LD and SD: 20% and 23.5%; PegIFN α2a: 31.5%).…”
Section: Treatment Efficacy In Hcv Patientsmentioning
confidence: 99%